Tirzepatide-Friend or Foe in Diabetic Cancer Patients?

ABSTRACT: It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals. A cancer patient managing their body weight and maintaining blood glucose control responds better to anti-cancer therapy than obese individuals and those whose blood glucose levels remain higher than normal during therapeutic intervention. In some cases, anti-diabetic/glucose-lowering drugs, some of which are also used to promote weight loss, were found t

SUBMITTER: Samuel SM 

PROVIDER: S-EPMC9687454 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature